Compare Novartis with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs FULFORD INDIA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS FULFORD INDIA NOVARTIS/
FULFORD INDIA
 
P/E (TTM) x 2,172.5 398.8 544.8% View Chart
P/BV x 28.8 6.2 464.1% View Chart
Dividend Yield % 1.5 0.1 1,809.1%  

Financials

 NOVARTIS   FULFORD INDIA
EQUITY SHARE DATA
    NOVARTIS
Mar-19
FULFORD INDIA
Mar-14
NOVARTIS/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs980942 104.0%   
Low Rs600450 133.4%   
Sales per share (Unadj.) Rs198.7691.4 28.7%  
Earnings per share (Unadj.) Rs21.011.5 182.9%  
Cash flow per share (Unadj.) Rs22.315.4 144.9%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.30.3 440.5%  
Book value per share (Unadj.) Rs307.5380.0 80.9%  
Shares outstanding (eoy) m24.693.90 633.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.01.0 394.9%   
Avg P/E ratio x37.760.7 62.1%  
P/CF ratio (eoy) x35.545.3 78.3%  
Price / Book Value ratio x2.61.8 140.3%  
Dividend payout %47.717.4 273.3%   
Avg Mkt Cap Rs m19,5082,714 718.7%   
No. of employees `0000.60.4 130.9%   
Total wages/salary Rs m1,171505 231.9%   
Avg. sales/employee Rs Th8,445.46,073.0 139.1%   
Avg. wages/employee Rs Th2,015.71,137.4 177.2%   
Avg. net profit/employee Rs Th891.0100.7 885.1%   
INCOME DATA
Net Sales Rs m4,9072,696 182.0%  
Other income Rs m783125 624.1%   
Total revenues Rs m5,6892,822 201.6%   
Gross profit Rs m123-46 -264.7%  
Depreciation Rs m3215 209.2%   
Interest Rs m1610 167.4%   
Profit before tax Rs m85854 1,579.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m34010 3,541.7%   
Profit after tax Rs m51845 1,158.2%  
Gross profit margin %2.5-1.7 -145.4%  
Effective tax rate %39.617.7 224.2%   
Net profit margin %10.61.7 636.4%  
BALANCE SHEET DATA
Current assets Rs m8,0551,738 463.4%   
Current liabilities Rs m1,850545 339.7%   
Net working cap to sales %126.444.3 285.6%  
Current ratio x4.43.2 136.4%  
Inventory Days Days4548 92.9%  
Debtors Days Days344 787.8%  
Net fixed assets Rs m15012 1,258.8%   
Share capital Rs m12339 316.4%   
"Free" reserves Rs m7,4691,443 517.6%   
Net worth Rs m7,5921,482 512.3%   
Long term debt Rs m00-   
Total assets Rs m9,8242,077 473.1%  
Interest coverage x54.96.7 818.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.51.3 38.5%   
Return on assets %5.42.6 208.1%  
Return on equity %6.83.0 226.1%  
Return on capital %11.54.3 267.3%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m5817 334.9%   
Fx outflow Rs m1,326673 197.0%   
Net fx Rs m-1,269-656 193.4%   
CASH FLOW
From Operations Rs m-1,94390 -2,158.7%  
From Investments Rs m2,742105 2,621.7%  
From Financial Activity Rs m-298-14 2,114.9%  
Net Cashflow Rs m501181 277.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 2.0 3.8 52.6%  
FIIs % 1.6 0.1 1,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 21.2 101.4%  
Shareholders   41,647 4,783 870.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   FDC LTD.  ALEMBIC LTD  WYETH LTD  AJANTA PHARMA  SUVEN LIFESCIENCES  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Crashes 433 Points; Banking and Auto Stocks Bleed(Closing)

Indian share markets ended on a negative note today amid a huge selloff in auto and banking stocks.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

3 Stocks to Ride the Big Rebound in Smallcaps(Profit Hunter)

Aug 11, 2020

The rebound ratio suggests that smallcaps are set for big gains but this time it will be limited to a few stocks. Make sure you choose wisely.

Governance: For the Country and Your Portfolio(The Honest Truth)

Aug 14, 2020

Ajit Dayal on the need of socially responsible governance.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 14, 2020 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - GSK PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS